CTKB
Cytek Biosciences, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$4.70
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 206.7M | 201.5M | 200.5M | 193.0M | 164.0M |
| Cost of Revenue | 96.7M | 97.0M | 89.3M | 83.6M | 63.1M |
| Gross Profit | 110.0M | 104.5M | 111.1M | 109.4M | 101.0M |
| Operating Expenses | |||||
| R&D Expense | 37.3M | 36.5M | 39.4M | 44.2M | 34.9M |
| SG&A Expense | 117.4M | 108.4M | 92.2M | 93.1M | 67.9M |
| General & Admin Expense | 67.8M | 58.9M | 43.1M | 44.0M | 34.7M |
| Selling & Marketing Expense | 49.6M | 49.4M | 49.1M | 49.1M | 33.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 154.7M | 144.8M | 131.6M | 137.3M | 102.8M |
| Cost and Expenses | 251.4M | 241.9M | 221.0M | 220.9M | 165.8M |
| Operating Income (EBIT) | (44.6M) | (40.4M) | (20.5M) | (27.8M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | 2.8M | 2.2M | 10.4M | 6.4M | 4.6M |
| Interest Expense | 1.8M | 474.0K | — | 2.1M | 2.6M |
| Net Interest Income | 997.0K | 1.7M | 10.4M | 4.3M | 2.0M |
| Other Non-Op Income/Expense | 3.8M | 10.5M | 14.8M | 12.1M | 3.1M |
| Non-Operating Income (excl Interest) | (5.6M) | (11.0M) | (14.8M) | (14.2M) | (5.6M) |
| EBT (Pre-Tax Income) | (40.8M) | (29.8M) | (5.7M) | (15.7M) | 1.3M |
| Income Tax Expense | 39.8M | 36.7M | 320.0K | (3.6M) | (1.2M) |
| Bottom Line | |||||
| Net Income | (80.6M) | (66.5M) | (6.0M) | (12.1M) | 2.6M |
| Earnings from Cont. Ops | (80.6M) | (66.5M) | (6.0M) | (12.1M) | 2.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (80.6M) | (66.5M) | (6.0M) | (12.1M) | 2.6M |
| Per Share | |||||
| Basic EPS | ($0.62) | ($0.52) | ($0.05) | ($0.09) | $0.02 |
| Diluted EPS | ($0.62) | ($0.52) | ($0.05) | ($0.09) | $0.02 |
| Revenue Per Share | $1.60 | $1.58 | $1.53 | $1.43 | $1.22 |
| Shares | |||||
| Basic Shares Outstanding | 129.5M | 127.7M | 130.6M | 135.3M | 134.5M |
| Diluted Shares Outstanding | 129.5M | 127.7M | 130.6M | 135.3M | 138.6M |
| Profitability Metrics | |||||
| EBITDA | (27.2M) | (17.4M) | 4.8M | (4.4M) | 9.5M |
| D&A | 11.9M | 12.0M | 10.5M | 9.2M | 5.7M |
| EBIT | (39.1M) | (29.4M) | (5.7M) | (13.6M) | 3.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026